Royalty Pharma plc Payments to Acquire Marketable Securities
Royalty Pharma plc (RPRX) reported Payments to Acquire Marketable Securities of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-12.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2025-02-12
- Royalty Pharma plc payments to acquire marketable securities for the quarter ending 2023-12-31 was $0.00.
- Royalty Pharma plc payments to acquire marketable securities for the quarter ending 2023-09-30 was $0.00.
- Royalty Pharma plc payments to acquire marketable securities for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- Royalty Pharma plc payments to acquire marketable securities for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- Royalty Pharma plc payments to acquire marketable securities for fiscal 2024 was $0.00.
- Royalty Pharma plc payments to acquire marketable securities for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Royalty Pharma plc payments to acquire marketable securities for fiscal 2022 was $234.87M, a 80.37% decline from fiscal 2021.
- Royalty Pharma plc payments to acquire marketable securities for fiscal 2021 was $1.20B, a 29.83% decline from fiscal 2020.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 6 month as first filed | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-12 | ||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $0.00 derived: sum of 2 quarters · filed 2025-02-12 | $0.00 derived: sum of 3 quarters · filed 2025-02-12 | $0.00 10-K · filed 2025-02-12 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $0.00 derived: sum of 2 quarters · filed 2023-11-08 | $0.00 10-Q · filed 2023-11-08 | $0.00 derived: sum of 4 quarters · filed 2025-02-12 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $0.00 10-Q · filed 2023-08-08 | $0.00 derived: sum of 3 quarters · filed 2025-02-12 | $0.00 derived: sum of 4 quarters · filed 2025-02-12 | |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-09 | $0.00 derived: sum of 2 quarters · filed 2025-02-12 | $0.00 derived: sum of 3 quarters · filed 2025-02-12 | $57.52M derived: sum of 4 quarters · filed 2025-02-12 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $0.00 derived: sum of 2 quarters · filed 2025-02-12 | $57.52M derived: sum of 3 quarters · filed 2025-02-12 | $234.87M 10-K · filed 2025-02-12 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $57.52M derived: sum of 2 quarters · filed 2023-11-08 | $234.87M 10-Q · filed 2023-11-08 | $675.78M derived: sum of 4 quarters · filed 2024-02-15 | |
| 2022-06-30 | $57.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $234.87M 10-Q · filed 2023-08-08 | $675.78M derived: sum of 3 quarters · filed 2024-02-15 | $703.42M derived: sum of 4 quarters · filed 2024-02-15 | |
| 2022-03-31 | $177.35M 10-Q · filed 2023-05-09 | $618.26M derived: sum of 2 quarters · filed 2024-02-15 | $645.91M derived: sum of 3 quarters · filed 2024-02-15 | $868.59M derived: sum of 4 quarters · filed 2024-02-15 | |
| 2021-12-31 | $440.91M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $468.55M derived: sum of 2 quarters · filed 2024-02-15 | $691.24M derived: sum of 3 quarters · filed 2024-02-15 | $1.20B 10-K · filed 2024-02-15 | |
| 2021-09-30 | $27.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $250.33M derived: sum of 2 quarters · filed 2022-11-08 | $755.67M 10-Q · filed 2022-11-08 | $1.37B derived: sum of 4 quarters · filed 2023-02-15 | |
| 2021-06-30 | $222.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $728.02M 10-Q · filed 2022-08-04 | $1.34B derived: sum of 3 quarters · filed 2023-02-15 | $1.73B derived: sum of 4 quarters · filed 2023-02-15 | |
| 2021-03-31 | $505.34M 10-Q · filed 2022-05-05 | $1.12B derived: sum of 2 quarters · filed 2023-02-15 | $1.51B derived: sum of 3 quarters · filed 2023-02-15 | $1.51B derived: sum of 4 quarters · filed 2023-02-15 | |
| 2020-12-31 | $610.02M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $1.00B derived: sum of 2 quarters · filed 2023-02-15 | $1.00B derived: sum of 3 quarters · filed 2023-02-15 | $1.71B 10-K · filed 2023-02-15 | |
| 2020-09-30 | $391.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $391.32M derived: sum of 2 quarters · filed 2021-11-10 | $1.10B 10-Q · filed 2021-11-10 | $1.16B derived: sum of 4 quarters · filed 2022-02-15 | |
| 2020-06-30 | -$1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $703.93M 10-Q · filed 2021-08-11 | $637.24M 10-Q · filed 2020-08-12 | $771.32M derived: sum of 3 quarters · filed 2022-02-15 | $1.52B derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | $703.93M 10-Q · filed 2021-05-11 | $771.32M derived: sum of 2 quarters · filed 2022-02-15 | $1.52B derived: sum of 3 quarters · filed 2022-02-15 | ||
| 2019-12-31 | $67.39M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $817.40M derived: sum of 2 quarters · filed 2022-02-15 | $817.40M 10-K · filed 2022-02-15 | ||
| 2019-09-30 | $750.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $750.01M 10-Q · filed 2020-11-12 | |||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-12 | ||||
| 2018-12-31 | $0.00 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |